netupitant
Sign in to saveAlso known as Ro 67-31898/000, Ro-673189000, 2-[3,5-Bis(trifluoromethyl)phenyl]-N,2-dimethyl-N-[4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinyl]propanamide
Netupitant is an antiemetic medication. In the United States, the combinations of netupitant/palonosetron and the prodrug fosnetupitant/palonosetron (both brand name Akynzeo) are approved by the Food and Drug Administration for the prevention of acute and delayed chemotherapy-induced nausea and vomiting, including highly emetogenic chemotherapy such as with cisplatin. In the European Union, the combinations are approved by the European Medicines Agency (EMA) for the same indication.
Research
222 papers- Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting.Drugs · 2021
- Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice.Current cancer drug targets · 2022
- Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting.Drugs · 2015
- Netupitant/palonosetron (Akynzeo) for chemotherapy-induced nausea and vomiting.The Medical letter on drugs and therapeutics · 2015
- Netupitant/Palonosetron.Hospital pharmacy · 2015
via PubMed
Wikidata facts
- Mass
- 578.248031
Show 4 more facts
- chemical formula
- C₃₀H₃₂F₆N₄O
- canonical SMILES
- CC1=CC=CC=C1C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4CCN(CC4)C
- World Health Organisation international non-proprietary name
- netupitant
- Commons category
- Netupitant
via Wikidata · CC0
~3 min read
Article
7 sectionsContents
- Adverse effects
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- References
- External links
Netupitant is an antiemetic medication. In the United States, the combinations of netupitant/palonosetron and the prodrug fosnetupitant/palonosetron (both brand name Akynzeo) are approved by the Food and Drug Administration for the prevention of acute and delayed chemotherapy-induced nausea and vomiting, including highly emetogenic chemotherapy such as with cisplatin. In the European Union, the combinations are approved by the European Medicines Agency (EMA) for the same indication.
==Adverse effects== Side effects of the combination netupitant/palonosetron are similar to palonosetron alone, so that no common side effects can be attributed to netupitant.